Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Oct 15, 2013; 4(5): 165-169
Published online Oct 15, 2013. doi: 10.4239/wjd.v4.i5.165
Published online Oct 15, 2013. doi: 10.4239/wjd.v4.i5.165
Current status in diabetic macular edema treatments
Pedro Romero-Aroca, Ophthalmology Service, Hospital Universitari Sant Joan, IISPV, Universidad Rovira i Virgili, 43203 Reus, Spain
Author contributions: Romero-Aroca P solely contributed to this paper.
Correspondence to: Pedro Romero-Aroca, MD, PhD, Professor, Ophthalmology Service, Hospital Universitari Sant Joan, IISPV, Universidad Rovira i Virgili, C/Ample 55 1º, 43203 Reus, Spain. romeropere@gmail.com
Telephone: +34-977-310300 Fax: +34-977-32375
Received: June 21, 2013
Revised: July 21, 2013
Accepted: September 18, 2013
Published online: October 15, 2013
Processing time: 117 Days and 8.8 Hours
Revised: July 21, 2013
Accepted: September 18, 2013
Published online: October 15, 2013
Processing time: 117 Days and 8.8 Hours
Core Tip
Core tip: Diabetic macular edema is the leading causes of decreased visual acuity in diabetic patients, being the most important blindness causes in young adult people. New treatments have been developed in the last years, intravitreal anti-vascular endothelial growth factor drugs, corticoid intravitreal implants or injections, but the laser photocoagulation being the gold standard of diabetic macular edema treatment. The following manuscript tries to clarify the current status of diabetic macular edema treatment.